Lumpectomy surgery for large ductal carcinoma in situ
- PMID: 39928263
- DOI: 10.1007/s10549-025-07621-w
Lumpectomy surgery for large ductal carcinoma in situ
Abstract
Purpose: Breast-conserving surgery for larger ductal carcinoma in situ (DCIS) remains limited. We compare the attempted use and success rates of lumpectomy surgery in patients with DCIS measuring ≥ 4 cm versus < 4 cm.
Methods: A retrospective review was conducted using the institutional tumor registry to identify cases of pure DCIS that were surgically treated from 2015 to 2022. Clinical-pathological data were abstracted from electronic medical records. Pathologic tumor size on initial surgery was used to define the two cohorts. Comparisons of variables were made using Chi-square and ANOVA tests.
Results: A total of 669 patients, 84% (562) with tumors measuring < 4 cm and 16% (107) ≥ 4 cm were identified. Lumpectomy was the initial surgery performed for 89% of women with lesions measuring < 4 cm on preoperative imaging studies compared to 64% of those ≥ 4 cm. Overall, 461 (92.9%) of 496 in the < 4 cm succeeded at lumpectomy compared to 36 (56.3%) of 64 in the ≥ 4 cm group. Re-excision lumpectomies or mastectomy were performed in 27% and 44% of the < 4 cm and ≥ 4 cm subgroups. Lumpectomy was achieved for 70% of women with tumors in the 4 to 5.9 cm range compared to 33% in the 6-7.9 cm and the ≥ 8 cm groups. There were no local recurrences in the ≥ 4 cm group at an average of 4.4 years follow-up.
Conclusion: Lumpectomy is a viable option for many patients with DCIS ≥ 4 cm, especially those measuring < 6 cm, though repeat re-excisions may be required after initial attempt.
Keywords: Ductal carcinoma in situ; Lumpectomy; Mastectomy.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Mitchell KB, Kuerer H (2015) Ductal carcinoma in situ: treatment update and current trends. Curr Oncol Rep 17:48. https://doi.org/10.1007/s11912-015-0473-x - DOI - PubMed
-
- Nash AL, Hwang ES (2023) The landmark series—ductal carcinoma in situ: the evolution of treatment. Ann Surg Oncol 30:3206–3214. https://doi.org/10.1245/s10434-023-13370-1 - DOI - PubMed
-
- Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16(2):441–452. https://doi.org/10.1200/JCO.1998.16.2.441 - DOI - PubMed
-
- Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. The Lancet 353(9169):1993–2000. https://doi.org/10.1016/S0140-6736(99)05036-9 - DOI
-
- Wärnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, Ringberg A, Karlsson P, Arnesson LG, Anderson H, Jirström K, Holmberg L (2014) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 10(32):3613–3618. https://doi.org/10.1200/JCO.2014.56.2595 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
